A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

By Iyer Renuka   Bharthuar Anubha  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 311-320

Informa Healthcare

Access to resources Recommend Favorite

A Simplified Protocol Employing Elacridar in Rodents: A Screening Model in Drug Discovery to Assess P-gp Mediated Efflux at the Blood Brain Barrier

By  

Drug Metabolism Letters, Vol. 6, Iss. 2, 2012-01 ,pp. : 134-144

Bentham Science Publishers

Access to resources Recommend Favorite

A Transcellular Assay to Assess the P-gp Inhibition in Early Stage of Drug Development

By  

Drug Metabolism Letters, Vol. 6, Iss. 4, 2012-12 ,pp. : 285-291

Bentham Science Publishers

Access to resources Recommend Favorite

Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 15, 2012-08 ,pp. : 1649-1659

Bentham Science Publishers

Access to resources Recommend Favorite

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3896-3901

Blackwell Publishing

Access to resources Recommend Favorite